Dr. Hakon Hakonarson, MD, PhD, is Professor of Pediatrics at the Perelman School of Medicine, University of Pennsylvania, CHOP’s Endowed Chair in Genomics Research and Director of the Center for Applied Genomics. Dr. Hakonarson leads a major commitment from CHOP to genomically characterize over 100,000 children, an initiative that has gained nationwide attention. Dr. Hakonarson is a Principal Investigator within the eMERGE, Kids First and the TOPMed genomics programs funded by the NIH. Dr. Hakonarson is ranked among “The World’s Most Influential Scientific Minds” (Thomson Reuters top 1%).
Dr. Hakonarson has previously held several senior posts within the biopharmaceutical industry, including as vice president of Clinical Sciences and Development at deCODE genetics, Inc. Dr. Hakonarson has been the principal investigator (PI) on multiple National Institute of Health-sponsored grants, including Neurodevelopmental Genomics: Trajectories of Complex Phenotypes, the largest research project ever supported by the National Institute of Mental Health.
Dr. Hakonarson has published numerous high-impact papers on genomic discoveries and their translations in some of the most prestigious scientific medical journals. Time Magazine listed Dr. Hakonarson’s autism gene discovery project, reported in Nature in 2009, among the top 10 medical breakthroughs of that year, and paper on a novel precision-based therapy in vascular malformation disorders was awarded among the top 10 clinical/translational papers in 2019 by the Clinical Research Forum. Dr. Hakonarson is a pioneer of large-scale genomics and drug development projects for optimized deliverables of novel precision-based therapies as presented here.
- Understand how genomic approaches are used to uncover genes and genetic variants that are used to inform precision-based therapies
Understand how genetic biomarkers are leveraged to select medications for repurposing opportunities aimed at high efficacy and low risk of adverse events
- Understand how artificial intelligence and “Big Data” are transforming medicine with respect to innovative therapies
This seminar was delivered as a Pediatric Grand Rounds Lecture at Children’s Hospital of Philadelphia, on October 5, 2022.
The work presented in the presentations, videos, and other content on this site (“Presentations”) includes publicly available medical evidence, a consensus of medical practitioners, and/or opinions of individual practitioners that may differ from consensus opinions. These Presentations are intended only to provide general information and need to be adapted for each specific patient based on the practitioner’s professional judgment, consideration of any unique circumstances, the needs of each patient and their family, the availability of various resources at the health care institution where the patient is located, and other factors. The Presentations are not intended to constitute medical advice or treatment, nor should they be relied upon as such. The Presentations are not intended to create a doctor-patient relationship between/among The Children’s Hospital of Philadelphia, its physicians and the individual patients in question. The information contained in these Presentations are general in nature, and do not and are not intended to refer to specific patients.
CHOP, The Children’s Hospital of Philadelphia Foundation and its or their affiliates, the authors, presenters, practitioners, editors, and others associated with the creation of the Presentations (“CHOP”) are not responsible for errors or omissions in the Presentations; for any outcomes a patient might experience where a clinician reviewed one or more such Presentations in connection with providing care for that patient; and/or for any and all third party content on the site or in the Presentations. CHOP makes no warranty, expressed or implied, with respect to the currency, completeness, applicability or accuracy of the Presentations. Application of the information in or to a particular situation remains the professional responsibility of the practitioner who is directly treating the patient.
To the extent that the Presentations include information regarding drug dosing, in view of ongoing research, changes in government regulations and the constant flow of information relating to drug therapy and drug reactions, the viewer should not rely on the Presentation content, but rather is urged to check the package insert for each drug for indications, dosage, warnings and precautions.
Some drugs and medical devices presented in the Presentations have United States Food and Drug Administration (FDA) clearance for limited use in restricted research settings. It is the responsibility of the practitioner to ascertain the FDA status of each drug or device planned for use in their clinical practice.
You shall indemnify, defend and hold harmless CHOP, The Children’s Hospital of Philadelphia Foundation, and its/their current and former employees, officers, and agents, trustees, and their respective successors, heirs and assigns (“Indemnitees”) against any claims, liability, damage, loss or expenses (including attorneys’ fees and expenses of litigation) in connection with any claims, suits, actions, demands or judgments arising directly or indirectly out of your reference to or use of the Presentations.
The Presentations are protected by copyright laws and in some cases patent laws, and all rights are reserved under such laws. No part of the Presentations may be reproduced in any form by any means, or utilized in any other way, absent prior written permission from the copyright owner.
By starting this module, you agree to our Content Disclaimer and Terms of Service.